Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New study suggests that having COVID-19 increases a person’s risk of developing psychiatric disorders, and that having a psychiatric disorder increases the chance of getting COVID-19. The study, published in The Lancet Psychiatry, used the TriNetX electronic health records of 69 million people in the USA including over 62,000 cases of COVID-19.

Facemask and open lock with lockdown written on it and a world map etched into it.

Researchers at the University of Oxford, Department of Psychiatry and NIHR Oxford Health Biomedical Research Centre, report the first large-scale evidence that COVID-19 survivors are at an increased risk of psychiatric disorders. 

  • Almost 1 in 5 people diagnosed with COVID-19 receive a psychiatric diagnosis within the next 3 months
  • 1 in 4 of these people had not had a psychiatric diagnosis before COVID-19
  • Patients with existing psychiatric disorders might be more likely to get COVID-19

In the 3 months following testing positive for COVID-19, 1 in 5 survivors were found to get a diagnosis of anxiety, depression, or insomnia, for the first time. This is about twice as likely as for other groups of patients over the same period. A diagnosis of dementia may also be commoner. COVID-19 was also associated with more new psychiatric diagnoses in people who already had a history of psychiatric problems. Overall, almost 20 per cent of people received a psychiatric diagnosis within 90 days of getting COVID-19. 

The full story is available on the Department of Psychiatry website

 

 

Similar stories

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

One high altitude explorer acknowledges another

NASA Astronaut and Physiologist Dr Jessica Meir unveils The Physiological Society blue plaque in honour of fellow pioneering Physiologist and Scientific Explorer Mabel FitzGerald.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.